EDIGENE JAPAN
EDIGENE JAPAN
Industry:
Biopharma Biotechnology Medical Device
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.edi-gene.com
Status:
Active
Similar Organizations
Nutrisynapzz
Nutrisynapzz is an emerging pharma company
Current Advisors List
Current Employees Featured
More informations about "EdiGENE Japan"
EdiGene Inc. - LinkedIn
EdiGene Inc. | 1,511 followers on LinkedIn. Edit the Code of Life, Creating Transformative Solutions for Serious Diseases. | EdiGene is a clinical-stage company focused on translating …See details»
EdiGENE Japan - Crunchbase Company Profile & Funding
EdiGENE Corporation is an emerging biotech company. There is no recent news or activity for this profile.See details»
CareNet, Inc. (headquarters: Chiyoda
Such as by using technology that they developed to explore gene therapeutic agents and advance research and development. Name: CareNet, Inc. Representative Director: Katsuhiro Fujii, …See details»
EdiGene (2) - Work in biotech
EdiGene, a clinical-stage biotech, aims to develop gene editing treatments for genetic diseases, including beta-thalassemia, lymphoma, and neuromuscular diseases. Their technology utilizes …See details»
EdiGene and Neukio Enter Collaboration to Develop Next …
Feb 9, 2022 BEIJING, SHANGHAI and CAMBRIDGE, MASS– (February 9, 2022) – EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into …See details»
EdiGene and Neukio Enter Collaboration to Develop Next …
Feb 9, 2022 EdiGene is a global, clinical-stage biotechnology company focused on translating gene- editing technologies into transformative therapies for patients with serious genetic …See details»
EdiGENE Japan - Drug pipelines, Patents, Clinical trials - Synapse
Explore EdiGENE Japan with its drug pipeline, therapeutic area, technology platform, .See details»
アドバイザー アドバイザー 広報・販促担当者
Title: 2024_0628グローバルフーズの実施体制図レガシー Created Date: 6/28/2024 5:28:15 PMSee details»
EdiGene Gets $67 Million Infusion to Bring Gene Editing to
Oct 13, 2020 EdiGene raked in approximately $67 million in a series B financing round to further their genome-editing pipeline and expand the team. The Beijing-based biotech is currently …See details»
Local private firms to step up innovation - Chinadaily.com.cn
Aug 10, 2021 This is especially the case for innovative biotech companies," said Wei Dong, CEO of Edi-Gene, a Beijing-based private biotech company developing genome editing …See details»
EdiGene raises $67M to take gene-editing therapies into humans
Oct 13, 2020 EdiGene has raised around $67 million to advance work on gene-editing therapies. The Beijing-based biotech will use the series B funding to progress a pipeline led by a beta …See details»
Edi Gene Profiles - Facebook
View the profiles of people named Edi Gene. Join Facebook to connect with Edi Gene and others you may know. Facebook gives people the power to share and...See details»
不切割DNA也能控制基因表达，edi-gene完成16亿日元B轮融资
Apr 12, 2019 edi-gene独特的技术平台CRISPR-GNDM（指导核苷酸定向调节）能够在不切割DNA或RNA的情况下定向控制基因表达，从而控制蛋白质的合成。 “edi-gene基因调控的新方 …See details»
EdiGene Biotechnology Moves into New R&D Center at
Nov 7, 2022 Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic …See details»
EdiGene to Present Latest Research on A Novel Surface Marker …
Nov 4, 2021 BEIJING and CAMBRIDGE, MASSACHUSETTS – (November 4, 2021) – EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into …See details»
EdiGene Enters Research Collaboration to Develop Gene-editing
Feb 11, 2022 BEIJING and CAMBRIDGE, MASS– (November 23, 2021) – EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into …See details»
EdiGene Gets China’s First Approval to Start Trials of Gene Editing …
Jan 19, 2021 The study of EdiGene’s gene editing therapy ET-01 will assess its safety and efficacy in the treatment of transfusion-dependent thalassemia, the Beijing-based firm said …See details»
China’s EdiGene Raises $62 Million to Develop Gene Therapies for …
Apr 23, 2021 In January, the Center for Drug Evaluation of China’s National Medical Products Administration approved EdiGene’s Investigational New Drug application for ET-01, a gene …See details»
EdiGene Announces Approval of its IND Application for its …
Jan 18, 2021 ET-01 is an investigational, autologous, ex vivo gene-editing therapy. The approved trial of ET-01 is a multicenter, open-label, single arm study designed to assess its …See details»